Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
An update from Keymed Biosciences, Inc. ( (HK:2162) ) is now available.
Keymed Biosciences Inc. has entered into a licensing agreement with Prolium for the global development and commercialization of CM355, excluding Asia in oncology indications. CM355, a CD20×CD3 bispecific antibody, is in clinical trials and has shown promising results in treating non-Hodgkin lymphoma. The agreement, which includes significant financial terms and milestone payments, positions Keymed strategically in the biopharmaceutical industry, potentially enhancing its market presence and financial standing.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc. is a biopharmaceutical company focused on developing innovative therapeutic products, particularly in the area of oncology and autoimmune diseases. The company is known for creating bispecific antibodies, with a significant market focus on both oncology and non-oncology fields.
YTD Price Performance: -5.18%
Average Trading Volume: 1,587,992
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$7.67B
For detailed information about 2162 stock, go to TipRanks’ Stock Analysis page.